| Size | Price | Stock |
|---|---|---|
| 5mg | $612 | In-stock |
| 10mg | $918 | In-stock |
| 25mg | $1653 | In-stock |
| 50mg | $2645 | In-stock |
| 100mg | $4230 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-114383 |
| M.Wt: | 529.65 |
| Formula: | C30H31N3O4S |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
ST-539 is an orally active USP30 inhibitor that crosses the blood-brain barrier, with an IC50 of 0.37 μM. ST-539 blocks USP30-mediated removal of ubiquitin from Parkin substrates, induces Parkin-mediated mitophagy and apoptosis during mitochondrial stress, and inhibits the AKT/mTOR signaling pathway. ST-539 can be used for research on T-cell leukemia, Parkinson's disease, and colon adenocarcinoma[1][2][3][4].
In Vitro:ST-539 improves the mitochondrial fitness of Pmel-1 antigen-specific CD8+ T cells, reduces the expression of exhaustion markers, and enhances effector function[3].
ST-539 (10 μM; added on day 4 of an 8-day culture and maintained through the remaining culture period) enhances mitochondrial efficiency and granzyme B in chronically stimulated human CBMC-derived CD8+ T cells while decreasing Lag3[3].
ST-539 restores mitophagy and mitochondrial fitness in chronically stimulated mouse CD8+ T cells while reducing exhaustion and increasing granzyme B[3].
ST-539 (41 ng/mL-10 µg/mL; 72 h) enhances MK-2206 (HY-108232)-mediated growth inhibition of Jurkat T leukemia cells[1].
ST-539 (48 h) produces synergistic effects with PI3K/Akt/mTOR inhibitors in Jurkat T leukemia cells, where Indirubin (HY-N0117) combined with ST-539 reduces cell growth by 48%[1].
ST-539 (10 μg/mL) has minimal direct cytotoxicity against MC38 tumor cells and a slight effect on T cell expansion[3].
ST-539 (24 h) enhances MK-2206-induced AKT inhibition and apoptosis in Jurkat T leukemia cells[1].
ST-539 (10 µg/mL; 48 h) enhances AKT/mTOR inhibitor-induced loss of cell viability in Hela Parkin USP30 cells[1].
ST-539 (10 µg/mL; 0-6 h) inhibits USP30 in Hela Parkin USP30 cells, reduces AKT levels, and promotes Parkin-mediated mitophagy and apoptosis during AO-induced mitochondrial stress[1].
ST-539 (3 μg/mL) restores A/O-induced mitophagy in USP30-overexpressing HeLa-Parkin cells[4].
ST-539 (1-3 μg/mL; 18 h) requires functional PINK1/Parkin to promote TOM20 ubiquitination and reduce TOM20 and NDP52 in HeLa-Parkin cells[4].
ST-539 (1-10 μg/mL) promotes USP30-inhibitable mitophagy in HeLa-Parkin cells and restores A/O-induced ubiquitination of TOM20 and degradation of TIM23 and TOM40[4].
ST-539 (compound 14) inhibits USP30 with an IC50 of 0.37 μM[2].
In Vivo:ST-539 (0.5 mg per mouse; oral gavage; once every other day) reduces MC38 tumor growth and enhances the mitochondrial fitness and granzyme B expression of tumor-infiltrating CD8+ T cells[3].
ST-539 (25 mg/kg/day; intraperitoneal injection; once daily; 5 doses in total) inhibits USP30 and selectively increases cardiac mitophagy in vivo without impairing cardiac function[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.